Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
Sponsor content
359 result(s) found, displaying 131 to 140
-
Prescription medicine registrationActive ingredients: pembrolizumab.
-
Designation or determinationOrphan drug
-
Designation or determinationProvisional determination
-
Prescription medicine decision summaryAustralian prescription medicine decision summary
-
Prescription medicine decision summaryTGA decision: Lagevrio (molnupiravir) is approved for the treatment of adults with COVID-19.
-
Prescription medicine registrationActive ingredients: molnupiravir.
-
Prescription medicine registrationActive ingredients: molnupiravir.
-
Prescription medicine registrationActive ingredients: pneumococcal purified capsular polysaccharides.
-
Prescription medicine registrationActive ingredients: pneumococcal purified capsular polysaccharides.
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd